drugset / Trial / NCT00192478

Open-Label, Dose-Escalation Study of 2 to 5 IM Doses of MEDI-524 at 3 mg/kg or 15 mg/kg; Children to be Followed for 90 Days After Their Last Dose of MEDI-524

NCT00192478

Phase 1/2 Completed 217 enrolled MedImmune LLC
RandomizedParallel-groupOpen-labelTreatment

Summary

MEDI-524 given for up to 5 doses at 3 and 15 mg/kg to high-risk children appeared to be safe and well tolerated.

Timeline

Start
2004-02
Primary completion
2006-05
Completion
2006-08

Drugs

EvaluationDrugModalityDoseRoute
Comparator Motavizumab Monoclonal antibody 3 mg/kg Intramuscular
Comparator Motavizumab Monoclonal antibody 15 mg/kg Intramuscular